v3.26.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 13 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Cash flows from operating activities              
Net loss $ (11,687)   $ (4,439)   $ (25,596) $ (31,347)  
Adjustments to reconcile net loss to net cash used in operating activities              
Depreciation and amortization expense         446 443  
Change in fair value - Senior Secured Convertible Note (1,041)   (6,841)   819 7,638 $ 819
Amortization of common stock payment for vendor service agreement         57 147  
Changes in operating assets and liabilities:              
Accounts receivable         (445) (328)  
Prepaid expenses and other current assets         (1,195) (942)  
Accounts payable         (303) (408)  
Accrued expenses and other current liabilities         (276) (407)  
Net cash flows used in operating activities         (23,398) (23,014)  
Cash flows from investing activities              
Purchase of equipment         (236) (118)  
Net cash flows used in investing activities         (236) (118)  
Cash flows from financing activities              
Proceeds – issue of Senior Secured Convertible Notes         0 360  
Tax withholdings on equity based compensation         (17) 0  
Proceeds – exercise of stock options         21 13  
Proceeds – issue common stock – Employee Stock Purchase Plan   $ 210   $ 141 210 141  
Net cash flows provided by financing activities         22,333 31,897  
Net (decrease) increase in cash         (1,301) 8,765  
Cash, beginning of period   $ 34,705   $ 22,358 34,705 22,358  
Cash, end of period $ 33,404   $ 31,123   33,404 31,123 $ 33,404
Registered Direct Offering [Member]              
Cash flows from financing activities              
Proceeds – issue of common stock         16,845 14,935  
Confidentially Marketed Public Offering [Member]              
Cash flows from financing activities              
Proceeds – issue of common stock         0 16,174  
At-the-market Offering [Member]              
Cash flows from financing activities              
Proceeds – issue of common stock         5,274 274  
PAVmed [Member]              
Changes in operating assets and liabilities:              
Due To: PAVmed Inc. - operating expenses, employee related costs, MSA Fee         (9) 16  
Lucid Diagnostics 2018 Equity Plan [Member]              
Adjustments to reconcile net loss to net cash used in operating activities              
Stock-based compensation         3,082 2,092  
PAVmed 2014 Equity Plan [Member]              
Adjustments to reconcile net loss to net cash used in operating activities              
Stock-based compensation         $ 22 $ 82